FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 339 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Insights Into the Biology of Response and Resistance to MAPK Pathway... October 16, 2024 Improving research with registered reports May 16, 2022 What People With Cancer and Survivors Should Know About Vaping: An... September 26, 2023 Washington Farmers Harvest Crops For Neighbor With Stage Four Cancer August 5, 2019 Load more HOT NEWS What People in Asian American and Pacific Islander Communities Should Know... Teen Helps Mom With Cancer Shave Her Head, Then Turns To... 2022 ASCO Annual Meeting Research Round Up: New Research in Lung... Will Ponsegromab Be a Game Changer for Cancer Cachexia?
